Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Up 29.9% in October

Alto Neuroscience, Inc. (NYSE:ANRO) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totalling 5,350,000 shares, a growth of 29.9% from the September 30th total of 4,120,000 shares. Currently, 24.1% of the company’s stock are short sold. Based on an average trading volume of 656,800 shares, the short-interest ratio is currently 8.1 days.

Institutional Investors Weigh In On Alto Neuroscience

Several hedge funds have recently bought and sold shares of ANRO. RA Capital Management L.P. bought a new position in shares of Alto Neuroscience during the first quarter worth approximately $21,267,000. Price T Rowe Associates Inc. MD acquired a new position in Alto Neuroscience in the 1st quarter valued at $9,788,000. Vanguard Group Inc. bought a new position in Alto Neuroscience during the 1st quarter worth $8,233,000. Jennison Associates LLC bought a new position in Alto Neuroscience during the 1st quarter worth $7,039,000. Finally, Artal Group S.A. acquired a new stake in shares of Alto Neuroscience during the first quarter worth $5,372,000.

Wall Street Analyst Weigh In

ANRO has been the subject of several recent research reports. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. RODMAN&RENSHAW cut shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird dropped their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Finally, Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.40.

Alto Neuroscience Trading Down 5.0 %

ANRO opened at $4.01 on Wednesday. The stock’s fifty day simple moving average is $11.78 and its 200 day simple moving average is $12.19. Alto Neuroscience has a 1-year low of $3.93 and a 1-year high of $24.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.85 and a current ratio of 19.85.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.07. Equities research analysts expect that Alto Neuroscience will post -2.63 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.